Navigation Links
Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
Date:2/27/2008

TAMPA, Fla., Feb. 27 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that its New Drug Application (NDA) for Durezol(TM) has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review. Sirion Therapeutics is seeking approval from the FDA for its investigational compound Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a twice-daily steroid, as a treatment for postoperative ocular inflammation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

Priority review is granted by the FDA to those drugs that have the potential to provide a significant improvement compared to marketed products. This designation results in a review period of six months from the date of receipt of the NDA. The FDA has issued an action date of June 26, 2008 under the Prescription Drug User Fee Act (PDUFA).

Data from two Phase 3 clinical studies in post-operative inflammation will be presented at the American Society of Cataract and Refractive Surgery 2008 Symposium and Congress on Tuesday, April 8, 2008 at 8:32 am in room 176B at McCormick Place West in Chicago, IL.

Durezol(TM) is the trademark of Sirion Therapeutics Inc. and is currently under review by the U.S. Food and Drug Administration and has not yet been cleared as the trade name for commercial use.

About Post-Operative Inflammation

Over five million ophthalmic surgeries are performed each year in the United States. Post-operative inflammation is a common occurrence following these procedures, and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. While the inflammation tends to be self-resolving, some cases can lead to other serious conditions if left untreated. As there is no way to predict which patients might develop inflammatory complications, doctors often prescribe steroids and/or NSAID drops to prevent it. Most often, inflammation lasts a relatively short time, though severe forms can persist for a longer period of time.

About Durezol(TM)

Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% is a topical ophthalmic steroid that has the potential to treat patients suffering from ocular inflammatory diseases, including post-operative inflammation. Durezol(TM) is a difluorinated derivative of prednisolone and has potent anti- inflammatory activity. The efficacy and safety of Durezol(TM) in ocular inflammatory diseases has been demonstrated in an extensive preclinical and clinical program in Japan.

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four compounds: difluprednate, a topical steroid for post- operative inflammation and uveitis; ganciclovir, a topical antiviral for herpetic keratitis; cyclosporine, a topical immunomodulator for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist for geographic atrophy associated with dry AMD. In addition, Sirion has preclinical programs in back of the eye diseases and allergy. For more information, please visit http://www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
2. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
3. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
4. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
5. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
6. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
7. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
8. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
9. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
10. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
11. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... This ... became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p ... ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for the ...
(Date:2/26/2017)... ... ... IndustryArchive.Org . is announcing a new way for B2B Sellers to promote ... for B.A.N.T. quality sales leads based on the Sellers decision to purchase a sales ... B2B buyers are controlling the sales process via the Internet and that ad targeting ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert standing desk solution ... advantages built into the home office sit stand solution are bold colors, a ... gain the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... education, networking and recognition opportunities as well as advocacy for the state and ... NJ on February 23. The Council's Innovation Forecast event highlights innovation throughout ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
(Date:2/27/2017)... The Dutch secure mobile phone ... at the security level RESTRICTED. The solution thus meets the ... the communication of classified information. ... Sectra and Samsung have a strategic ... solution. Sectra Tiger/R is developed by Sectra under guidance from ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology: